Deutsch English Français

Contact

EP1845961

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1845961

EP1845961 - TREATMENT OF THROMBOEMBOLIC DISORDERS WITH RIVAROXABAN [Right-click to bookmark this link]
Former [2007/43]	PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISORDERS
	[2014/43]
Status	Opposition rejected Status updated on 29.06.2022 Database last updated on 03.04.2025
Former	The patent has been granted Status updated on 30.04.2018
Most recent event Tooltip	29.12.2023	Petition for review: decision	published on 31.01.2024 [2024/05]
Applicant(s)	For all designated states Bayer Intellectual Property GmbH Alfred-Nobel-Strasse 10 40789 Monheim / DE
	[2012/39]
Former [2011/34]	For all designated states Bayer Pharma Aktiengesellschaft Müllerstrasse 178 13353 Berlin / DE
Former [2009/38]	For all designated states Bayer Schering Pharma Aktiengesellschaft Müllerstrasse 178 13353 Berlin / DE
Former [2009/37]	For all designated states Bayer Schering Pharma AG Müllerstrasse 178 13353 Berlin / DE
Former [2007/43]	For all designated states Bayer HealthCare AG 51368 Leverkusen / DE
Inventor(s)	01 / MISSELWITZ, Frank Wielandtstr. 15 69120 Heidelberg / DE
	02 / KUBITZA, Dagmar Hegelstr. 40 40882 Ratingen / DE
	03 / PARK, Son-Mi Giveonstr. 21 42287 Wuppertal / DE
	04 / WEHLING, Klaus Am Rohm 121 42113 Wuppertal / DE
	[2007/43]
Representative(s)	Cohausz & Florack Patent- & Rechtsanwälte Partnerschaftsgesellschaft mbB Postfach 10 18 30 40009 Düsseldorf / DE
	[N/P]
Former [2015/17]	BIP Patents c/o Bayer Intellectual Property GmbH Creative Campus Monheim Alfred-Nobel-Straße 10 40789 Monheim / DE
Former [N/P]	BIP Patents c/o Bayer Intellectual Property GmbH Creative Campus Monheim Alfred-Nobel-Straße 10 DE-40789 Monheim / DE
Former [2013/01]	BIP Patents Creative Campus Monheim Alfred-Nobel-Straße 10 40789 Monheim / DE
Former [2012/39]	Bayer Intellectual Property GmbH Creative Campus Monheim Alfred-Nobel-Straße 10 40789 Monheim / DE
Application number, filing date	06706291.9	19.01.2006
	[2007/43]
	WO2006EP00431
Priority number, date	EP20050001893	31.01.2005 Original published format: EP 05001893
	[2007/43]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2006079474
	Date:	03.08.2006
	Language:	EN
	[2006/31]
	Type:	A1 Application with search report
	No.:	EP1845961
	Date:	24.10.2007
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 03.08.2006 takes the place of the publication of the European patent application.
	[2007/43]
	Type:	B1 Patent specification
	No.:	EP1845961
	Date:	22.04.2015
	Language:	EN
	[2015/17]
Search report(s)	International search report - published on:	EP	03.08.2006
Classification	IPC:	A61K31/00, A61K31/5377, A61P7/02, A61P9/10	[2007/43]
	CPC:	A61K31/00 (EP,NO,US); A61K31/5377 (EP,KR,NO,US); A61P7/00 (EP); A61P7/02 (EP,NO); A61P9/00 (EP,NO); A61P9/08 (EP); (+) A61P9/10 (EP) (-)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2015/17]
Former [2007/43]	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
Extension states	HR	31.08.2007
Title	German:	THERAPIE VON THROMBOEMBOLISCHEN STÖRUNGEN MIT RIVAROXABAN	[2014/43]
	English:	TREATMENT OF THROMBOEMBOLIC DISORDERS WITH RIVAROXABAN	[2014/43]
	French:	TRAITEMENT DE TROUBLES THROMBOEMBOLIQUES AVEC DU RIVAROXABAN	[2014/43]
	Former [2007/43]	PRÄVENTION UND THERAPIE VON THROMBOEMBOLISCHEN STÖRUNGEN
	Former [2007/43]	PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISORDERS
	Former [2007/43]	PREVENTION ET TRAITEMENT DE TROUBLES THROMBOEMBOLIQUES
Entry into regional phase	31.08.2007	National basic fee paid
	31.08.2007	Designation fee(s) paid
	31.08.2007	Examination fee paid
Examination procedure	31.08.2007	Examination requested [2007/43]
	26.07.2010	Despatch of a communication from the examining division (Time limit: M06)
	24.01.2011	Reply to a communication from the examining division
	02.04.2012	Despatch of a communication from the examining division (Time limit: M06)
	26.09.2012	Reply to a communication from the examining division
	28.04.2014	Observations by third parties
	13.11.2014	Communication of intention to grant the patent
	05.02.2015	Observations by third parties
	11.03.2015	Fee for grant paid
	11.03.2015	Fee for publishing/printing paid
	11.03.2015	Receipt of the translation of the claim(s)
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 26.07.2010
Opposition(s)	Opponent(s)	01 22.07.2015 11.01.2016 WITHDRAWN Breuer, Markus Henkel, Breuer & Partner Patentanwälte Brienner Str. 1 80333 München / DE Opponent's representative Ferrer Internacional S.A. Joan Buscallà 1-9 08173 Sant Cugat del Vallès / ES
		02 06.01.2016 19.01.2016 ADMISSIBLE Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		03 21.01.2016 29.01.2016 ADMISSIBLE ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. ul. Pelplinska 19 83-200 Starogard Gdanski / PL Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		04 21.01.2016 29.01.2016 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St. 6944020 Tel Aviv / IL Opponent's representative Elkington and Fife LLP, et al, et al Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		05 21.01.2016 03.02.2016 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 21.01.2016 29.01.2016 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Building 4 Trident Place Mosquito Way Hatfield Hertfordshire AL10 9UL / GB Opponent's representative Elend, Almut Susanne, et al, et al Venner Shipley LLP 406 Cambridge Science Park Milton Road Cambridge CB4 0WW / GB
		07 21.01.2016 25.01.2016 ADMISSIBLE Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Sanayi Mah. Tunc Cad.No:3 Esenyurt 34555 Istanbul / TR
		08 21.01.2016 02.02.2016 ADMISSIBLE Wittkopp, Alexander Bogenallee 5 20144 Hamburg / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE
		09 22.01.2016 03.02.2016 ADMISSIBLE Galenicum Health S.L. Avenida Diagonal 123, 11th floor 08005 Barcelona / ES Opponent's representative Galenicum Health S.L.U. Avinguda de Cornellà 144, 7th floor 08950 Esplugues de Llobregat / ES
		10 26.01.2016 03.02.2016 ADMISSIBLE ABG Intellectual Property Law, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES Opponent's representative ABG Intellectual Property Law, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES
		11 22.01.2016 03.02.2016 ADMISSIBLE Stolmár, Matthias Blumenstrasse 17 80331 München / DE Opponent's representative Stolmár & Partner Patentanwälte PartG mbB Blumenstraße 17 80331 München / DE
		12 22.01.2016 03.02.2016 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstraße 2 80538 München / DE
		13 22.01.2016 03.02.2016 ADMISSIBLE Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE Opponent's representative Adam, Holger Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE
		14 19.03.2021 28.01.2021 INTERVENTION Zentiva, k.s. U kabelovny 130 102 37 Praha 10 - Dolni Mecholupy / CZ Opponent's representative Ellis, Robin Patrick Reddie & Grose LLP The White Chapel Building 10 Whitechapel High Street London E1 8QS / GB
		15 14.04.2021 22.04.2021 INTERVENTION Krka, d.d., Novo mesto Smarjeska cesta 6 8000 Novo mesto / SI Opponent's representative Hoefer & Partner Patentanwälte mbB Pilgersheimer Straße 20 81543 München / DE
		[N/P]
	Former [2021/48]
	Opponent(s)	01 22.07.2015 11.01.2016 WITHDRAWN Breuer, Markus Henkel, Breuer & Partner Patentanwälte Brienner Str. 1 80333 München / DE Opponent's representative Ferrer Internacional S.A. Joan Buscallà 1-9 08173 Sant Cugat del Vallès / ES
		02 06.01.2016 19.01.2016 ADMISSIBLE Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		03 21.01.2016 29.01.2016 ADMISSIBLE ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. ul. Pelplinska 19 83-200 Starogard Gdanski / PL Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		04 21.01.2016 29.01.2016 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St. 6944020 Tel Aviv / IL Opponent's representative Elkington and Fife LLP, et al, et al Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		05 21.01.2016 03.02.2016 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 21.01.2016 29.01.2016 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Building 4 Trident Place Mosquito Way Hatfield Hertfordshire AL10 9UL / GB Opponent's representative Elend, Almut Susanne, et al, et al Venner Shipley LLP Byron House Cambridge Business Park Cowley Road Cambridge, Cambridgeshire CB4 0WZ / GB
		07 21.01.2016 25.01.2016 ADMISSIBLE Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Sanayi Mah. Tunc Cad.No:3 Esenyurt 34555 Istanbul / TR
		08 21.01.2016 02.02.2016 ADMISSIBLE Wittkopp, Alexander Bogenallee 5 20144 Hamburg / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE
		09 22.01.2016 03.02.2016 ADMISSIBLE Galenicum Health S.L. Avenida Diagonal 123, 11th floor 08005 Barcelona / ES Opponent's representative Galenicum Health S.L.U. Avinguda de Cornellà 144, 7th floor 08950 Esplugues de Llobregat / ES
		10 26.01.2016 03.02.2016 ADMISSIBLE ABG Intellectual Property Law, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES Opponent's representative ABG Intellectual Property Law, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES
		11 22.01.2016 03.02.2016 ADMISSIBLE Stolmár, Matthias Blumenstrasse 17 80331 München / DE Opponent's representative Stolmár & Partner Patentanwälte PartG mbB Blumenstraße 17 80331 München / DE
		12 22.01.2016 03.02.2016 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstraße 2 80538 München / DE
		13 22.01.2016 03.02.2016 ADMISSIBLE Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE Opponent's representative Adam, Holger Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE
		14 19.03.2021 28.01.2021 INTERVENTION Zentiva, k.s. U kabelovny 130 102 37 Praha 10 - Dolni Mecholupy / CZ Opponent's representative Ellis, Robin Patrick Reddie & Grose LLP The White Chapel Building 10 Whitechapel High Street London E1 8QS / GB
		15 14.04.2021 22.04.2021 INTERVENTION Krka, d.d., Novo mesto Smarjeska cesta 6 8000 Novo mesto / SI Opponent's representative Hoefer & Partner Patentanwälte mbB Pilgersheimer Straße 20 81543 München / DE
	Former [2021/47]
	Opponent(s)	01 22.07.2015 11.01.2016 WITHDRAWN Breuer, Markus Henkel, Breuer & Partner Patentanwälte Brienner Str. 1 80333 München / DE Opponent's representative Ferrer Internacional S.A. Joan Buscallà 1-9 08173 Sant Cugat del Vallès / ES
		02 06.01.2016 19.01.2016 ADMISSIBLE Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		03 21.01.2016 29.01.2016 ADMISSIBLE ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. ul. Pelplinska 19 83-200 Starogard Gdanski / PL Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		04 21.01.2016 29.01.2016 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St. 6944020 Tel Aviv / IL Opponent's representative Elkington and Fife LLP, et al, et al Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		05 21.01.2016 03.02.2016 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 21.01.2016 29.01.2016 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Building 4 Trident Place Mosquito Way Hatfield Hertfordshire AL10 9UL / GB Opponent's representative Elend, Almut Susanne, et al, et al Venner Shipley LLP Byron House Cambridge Business Park Cowley Road Cambridge, Cambridgeshire CB4 0WZ / GB
		07 21.01.2016 25.01.2016 ADMISSIBLE Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Sanayi Mah. Tunc Cad.No:3 Esenyurt 34555 Istanbul / TR
		08 21.01.2016 02.02.2016 ADMISSIBLE Wittkopp, Alexander Bogenallee 5 20144 Hamburg / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE
		09 22.01.2016 03.02.2016 ADMISSIBLE Galenicum Health S.L. Avenida Diagonal 123, 11th floor 08005 Barcelona / ES Opponent's representative Galenicum Health S.L.U. Avinguda de Cornellà 144, 7th floor 08950 Esplugues de Llobregat / ES
		10 26.01.2016 03.02.2016 ADMISSIBLE ABG Intellectual Property Law, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES Opponent's representative ABG Intellectual Property Law, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES
		11 22.01.2016 03.02.2016 ADMISSIBLE Stolmár, Matthias Blumenstrasse 17 80331 München / DE Opponent's representative Stolmár & Partner Patentanwälte PartG mbB Blumenstraße 17 80331 München / DE
		12 22.01.2016 03.02.2016 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstraße 2 80538 München / DE
		13 22.01.2016 03.02.2016 ADMISSIBLE Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE Opponent's representative Adam, Holger Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE
		14 19.03.2021 28.01.2021 INTERVENTION Zentiva Group, a.s. U Kabelovny 130 102 37 Prague / CZ Opponent's representative Ellis, Robin Patrick Reddie & Grose LLP The White Chapel Building 10 Whitechapel High Street London E1 8QS / GB
		15 14.04.2021 22.04.2021 INTERVENTION Krka, d.d., Novo mesto Smarjeska cesta 6 8000 Novo mesto / SI Opponent's representative Hoefer & Partner Patentanwälte mbB Pilgersheimer Straße 20 81543 München / DE
	Former [2021/21]
	Opponent(s)	01 22.07.2015 11.01.2016 WITHDRAWN Breuer, Markus Henkel, Breuer & Partner Patentanwälte Brienner Str. 1 80333 München / DE Opponent's representative Ferrer Internacional S.A. Joan Buscallà 1-9 08173 Sant Cugat del Vallès / ES
		02 06.01.2016 19.01.2016 ADMISSIBLE Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		03 21.01.2016 29.01.2016 ADMISSIBLE ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. ul. Pelplinska 19 83-200 Starogard Gdanski / PL Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		04 21.01.2016 29.01.2016 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 5 Basel Street Petach Tikva 49131 / IL Opponent's representative Elkington and Fife LLP, et al, et al Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		05 21.01.2016 03.02.2016 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 21.01.2016 29.01.2016 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Building 4 Trident Place Mosquito Way Hatfield Hertfordshire AL10 9UL / GB Opponent's representative Elend, Almut Susanne, et al, et al Venner Shipley LLP Byron House Cambridge Business Park Cowley Road Cambridge, Cambridgeshire CB4 0WZ / GB
		07 21.01.2016 25.01.2016 ADMISSIBLE Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Sanayi Mah. Tunc Cad.No:3 Esenyurt 34555 Istanbul / TR
		08 21.01.2016 02.02.2016 ADMISSIBLE Wittkopp, Alexander Bogenallee 5 20144 Hamburg / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE
		09 22.01.2016 03.02.2016 ADMISSIBLE Galenicum Health S.L. Avenida Diagonal 123, 11th floor 08005 Barcelona / ES Opponent's representative Galenicum Health S.L. Avinguda de Cornellà 144, 7th floor 08950 Esplugues de Llobregat / ES
		10 26.01.2016 03.02.2016 ADMISSIBLE ABG Intellectual Property Law, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES Opponent's representative ABG Intellectual Property Law, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES
		11 22.01.2016 03.02.2016 ADMISSIBLE Stolmár, Matthias Blumenstrasse 17 80331 München / DE Opponent's representative Stolmár & Partner Patentanwälte PartG mbB Blumenstraße 17 80331 München / DE
		12 22.01.2016 03.02.2016 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstraße 2 80538 München / DE
		13 22.01.2016 03.02.2016 ADMISSIBLE Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE Opponent's representative Adam, Holger Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE
		14 19.03.2021 28.01.2021 INTERVENTION Zentiva Group, a.s. U Kabelovny 130 102 37 Prague / CZ Opponent's representative Ellis, Robin Patrick Reddie & Grose LLP The White Chapel Building 10 Whitechapel High Street London E1 8QS / GB
		15 14.04.2021 22.04.2021 INTERVENTION Krka, d.d., Novo mesto Smarjeska cesta 6 8000 Novo mesto / SI Opponent's representative Hoefer & Partner Patentanwälte mbB Pilgersheimer Straße 20 81543 München / DE
	Former [2021/20]
	Opponent(s)	01 22.07.2015 11.01.2016 WITHDRAWN Breuer, Markus Henkel, Breuer & Partner Patentanwälte Brienner Str. 1 80333 München / DE Opponent's representative Ferrer Internacional S.A. Joan Buscallà 1-9 08173 Sant Cugat del Vallès / ES
		02 06.01.2016 19.01.2016 ADMISSIBLE Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		03 21.01.2016 29.01.2016 ADMISSIBLE ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. ul. Pelplinska 19 83-200 Starogard Gdanski / PL Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		04 21.01.2016 29.01.2016 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 5 Basel Street Petach Tikva 49131 / IL Opponent's representative Elkington and Fife LLP, et al, et al Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		05 21.01.2016 03.02.2016 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 21.01.2016 29.01.2016 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Building 4 Trident Place Mosquito Way Hatfield Hertfordshire AL10 9UL / GB Opponent's representative Elend, Almut Susanne, et al, et al Venner Shipley LLP Byron House Cambridge Business Park Cowley Road Cambridge, Cambridgeshire CB4 0WZ / GB
		07 21.01.2016 25.01.2016 ADMISSIBLE Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Sanayi Mah. Tunc Cad.No:3 Esenyurt 34555 Istanbul / TR
		08 21.01.2016 02.02.2016 ADMISSIBLE Wittkopp, Alexander Bogenallee 5 20144 Hamburg / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE
		09 22.01.2016 03.02.2016 ADMISSIBLE Galenicum Health S.L. Avenida Diagonal 123, 11th floor 08005 Barcelona / ES Opponent's representative Galenicum Health S.L. Avinguda de Cornellà 144, 7th floor 08950 Esplugues de Llobregat / ES
		10 26.01.2016 03.02.2016 ADMISSIBLE ABG Intellectual Property Law, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES Opponent's representative ABG Intellectual Property Law, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES
		11 22.01.2016 03.02.2016 ADMISSIBLE Stolmár, Matthias Blumenstrasse 17 80331 München / DE Opponent's representative Stolmár & Partner Patentanwälte PartG mbB Blumenstraße 17 80331 München / DE
		12 22.01.2016 03.02.2016 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstraße 2 80538 München / DE
		13 22.01.2016 03.02.2016 ADMISSIBLE Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE Opponent's representative Adam, Holger Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE
		14 19.03.2021 28.01.2021 INTERVENTION Zentiva Group, a.s. U Kabelovny 130 102 37 Prague / CZ Opponent's representative Ellis, Robin Patrick Reddie & Grose LLP The White Chapel Building 10 Whitechapel High Street London E1 8QS / GB
	Former [2021/18]
	Opponent(s)	01 22.07.2015 11.01.2016 WITHDRAWN Breuer, Markus Henkel, Breuer & Partner Patentanwälte Brienner Str. 1 80333 München / DE Opponent's representative Ferrer Internacional S.A. Joan Buscallà 1-9 08173 Sant Cugat del Vallès / ES
		02 06.01.2016 19.01.2016 ADMISSIBLE Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		03 21.01.2016 29.01.2016 ADMISSIBLE ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. ul. Pelplinska 19 83-200 Starogard Gdanski / PL Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		04 21.01.2016 29.01.2016 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 5 Basel Street Petach Tikva 49131 / IL Opponent's representative Elkington and Fife LLP, et al, et al Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		05 21.01.2016 03.02.2016 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 21.01.2016 29.01.2016 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Building 4 Trident Place Mosquito Way Hatfield Hertfordshire AL10 9UL / GB Opponent's representative Elend, Almut Susanne, et al, et al Venner Shipley LLP Byron House Cambridge Business Park Cowley Road Cambridge, Cambridgeshire CB4 0WZ / GB
		07 21.01.2016 25.01.2016 ADMISSIBLE Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Sanayi Mah. Tunc Cad.No:3 Esenyurt 34555 Istanbul / TR
		08 21.01.2016 02.02.2016 ADMISSIBLE Wittkopp, Alexander Bogenallee 5 20144 Hamburg / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE
		09 22.01.2016 03.02.2016 ADMISSIBLE Galenicum Health S.L. Avenida Diagonal 123, 11th floor 08005 Barcelona / ES Opponent's representative Galenicum Health S.L. Avenida de Cornellà 144, 7th floor 08950 Esplugues de Llobregat / ES
		10 26.01.2016 03.02.2016 ADMISSIBLE ABG Intellectual Property Law, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES Opponent's representative ABG Intellectual Property Law, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES
		11 22.01.2016 03.02.2016 ADMISSIBLE Stolmár, Matthias Blumenstrasse 17 80331 München / DE Opponent's representative Stolmár & Partner Patentanwälte PartG mbB Blumenstraße 17 80331 München / DE
		12 22.01.2016 03.02.2016 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstraße 2 80538 München / DE
		13 22.01.2016 03.02.2016 ADMISSIBLE Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE Opponent's representative Adam, Holger Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE
		14 19.03.2021 28.01.2021 INTERVENTION Zentiva Group, a.s. U Kabelovny 130 102 37 Prague / CZ Opponent's representative Ellis, Robin Patrick Reddie & Grose LLP The White Chapel Building 10 Whitechapel High Street London E1 8QS / GB
	Former [2021/13]
	Opponent(s)	01 22.07.2015 11.01.2016 WITHDRAWN Breuer, Markus Henkel, Breuer & Partner Patentanwälte Brienner Str. 1 80333 München / DE Opponent's representative Ferrer Internacional S.A. Joan Buscallà 1-9 08173 Sant Cugat del Vallès / ES
		02 06.01.2016 19.01.2016 ADMISSIBLE Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		03 21.01.2016 29.01.2016 ADMISSIBLE ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. ul. Pelplinska 19 83-200 Starogard Gdanski / PL Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		04 21.01.2016 29.01.2016 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 5 Basel Street Petach Tikva 49131 / IL Opponent's representative Elkington and Fife LLP, et al, et al Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		05 21.01.2016 03.02.2016 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 21.01.2016 29.01.2016 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Building 4 Trident Place Mosquito Way Hatfield Hertfordshire AL10 9UL / GB Opponent's representative Elend, Almut Susanne, et al, et al Venner Shipley LLP Byron House Cambridge Business Park Cowley Road Cambridge, Cambridgeshire CB4 0WZ / GB
		07 21.01.2016 25.01.2016 ADMISSIBLE Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Sanayi Mah. Tunc Cad.No:3 Esenyurt 34555 Istanbul / TR
		08 21.01.2016 02.02.2016 ADMISSIBLE Wittkopp, Alexander Bogenallee 5 20144 Hamburg / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE
		09 22.01.2016 03.02.2016 ADMISSIBLE Galenicum Health S.L. Avenida Diagonal 123, 11th floor 08005 Barcelona / ES Opponent's representative Galenicum Health S.L. Avenida de Cornellà 144, 7th floor 08950 Esplugues de Llobregat / ES
		10 26.01.2016 03.02.2016 ADMISSIBLE ABG Intellectual Property Law, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES Opponent's representative ABG Intellectual Property Law, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES
		11 22.01.2016 03.02.2016 ADMISSIBLE Stolmár, Matthias Blumenstrasse 17 80331 München / DE Opponent's representative Stolmár & Partner Patentanwälte PartG mbB Blumenstraße 17 80331 München / DE
		12 22.01.2016 03.02.2016 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstraße 2 80538 München / DE
		13 22.01.2016 03.02.2016 ADMISSIBLE Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE Opponent's representative Adam, Holger Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE
	Former [2021/03]
	Opponent(s)	01 22.07.2015 11.01.2016 WITHDRAWN Breuer, Markus Henkel, Breuer & Partner Patentanwälte Brienner Str. 1 80333 München / DE Opponent's representative Ferrer Internacional S.A. Joan Buscallà 1-9 08173 Sant Cugat del Vallès / ES
		02 06.01.2016 19.01.2016 ADMISSIBLE Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		03 21.01.2016 29.01.2016 ADMISSIBLE ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. ul. Pelplinska 19 83-200 Starogard Gdanski / PL Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		04 21.01.2016 29.01.2016 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 5 Basel Street Petach Tikva 49131 / IL Opponent's representative Elkington and Fife LLP, et al, et al Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		05 21.01.2016 03.02.2016 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 21.01.2016 29.01.2016 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Building 4 Trident Place Mosquito Way Hatfield Hertfordshire AL10 9UL / GB Opponent's representative Elend, Almut Susanne, et al, et al Venner Shipley LLP Byron House Cambridge Business Park Cowley Road Cambridge, Cambridgeshire CB4 0WZ / GB
		07 21.01.2016 25.01.2016 ADMISSIBLE Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Sanayi Mah. Tunc Cad.No:3 Esenyurt 34555 Istanbul / TR
		08 21.01.2016 02.02.2016 ADMISSIBLE Wittkopp, Alexander Bogenallee 5 20144 Hamburg / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE
		09 22.01.2016 03.02.2016 ADMISSIBLE Galenicum Health S.L. Avenida Diagonal 123, 11th floor 08005 Barcelona / ES Opponent's representative Galenicum Health S.L. Avenida de Cornellà 144, 7th floor 08950 Esplugues de Llobregat / ES
		10 26.01.2016 03.02.2016 ADMISSIBLE ABG Intellectual Property Law, S.L. Avenida de Burgos 16D Edificio Euromor 28036 Madrid / ES Opponent's representative ABG Intellectual Property Law, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES
		11 22.01.2016 03.02.2016 ADMISSIBLE Stolmár, Matthias Blumenstrasse 17 80331 München / DE Opponent's representative Stolmár & Partner Patentanwälte PartG mbB Blumenstraße 17 80331 München / DE
		12 22.01.2016 03.02.2016 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstraße 2 80538 München / DE
		13 22.01.2016 03.02.2016 ADMISSIBLE Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE Opponent's representative Adam, Holger Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE
	Former [2020/50]
	Opponent(s)	01 22.07.2015 11.01.2016 WITHDRAWN Breuer, Markus Henkel, Breuer & Partner Patentanwälte Brienner Str. 1 80333 München / DE Opponent's representative Ferrer Internacional S.A. Joan Buscallà 1-9 08173 Sant Cugat del Vallès / ES
		02 06.01.2016 19.01.2016 ADMISSIBLE Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		03 21.01.2016 29.01.2016 ADMISSIBLE ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. ul. Pelplinska 19 83-200 Starogard Gdanski / PL Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		04 21.01.2016 29.01.2016 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 5 Basel Street Petach Tikva 49131 / IL Opponent's representative Elkington and Fife LLP, et al, et al Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		05 21.01.2016 03.02.2016 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 21.01.2016 29.01.2016 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Building 4 Trident Place Mosquito Way Hatfield Hertfordshire AL10 9UL / GB Opponent's representative Elend, Almut Susanne, et al, et al Venner Shipley LLP Byron House Cambridge Business Park Cowley Road Cambridge, Cambridgeshire CB4 0WZ / GB
		07 21.01.2016 25.01.2016 ADMISSIBLE Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Sanayi Mah. Tunc Cad.No:3 Esenyurt 34555 Istanbul / TR
		08 21.01.2016 02.02.2016 ADMISSIBLE Wittkopp, Alexander Bogenallee 5 20144 Hamburg / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE
		09 22.01.2016 03.02.2016 ADMISSIBLE Galenicum Health S.L. Avenida Diagonal 123, 11th floor 08005 Barcelona / ES Opponent's representative Galenicum Health S.L. Avenida de Cornellà 144, 7th floor 08950 Esplugues de Llobregat / ES
		10 26.01.2016 03.02.2016 ADMISSIBLE ABG Intellectual Property Law, S.L. Avenida de Burgos 16D Edificio Euromor 28036 Madrid / ES Opponent's representative ABG Intellectual Property Law, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES
		11 22.01.2016 03.02.2016 ADMISSIBLE Stolmár, Matthias Blumenstrasse 17 80331 München / DE Opponent's representative Stolmár & Partner Patentanwälte PartG mbB Blumenstraße 17 80331 München / DE
		12 22.01.2016 03.02.2016 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Best, Michael Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstrasse 2 80538 München / DE
		13 22.01.2016 03.02.2016 ADMISSIBLE Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE Opponent's representative Adam, Holger Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE
	Former [2019/35]
	Opponent(s)	01 22.07.2015 11.01.2016 ADMISSIBLE Breuer, Markus Henkel, Breuer & Partner Patentanwälte Brienner Str. 1 80333 München / DE Opponent's representative Ferrer Internacional S.A. Joan Buscallà 1-9 08173 Sant Cugat del Vallès / ES
		02 06.01.2016 19.01.2016 ADMISSIBLE Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		03 21.01.2016 29.01.2016 ADMISSIBLE ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. ul. Pelplinska 19 83-200 Starogard Gdanski / PL Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		04 21.01.2016 29.01.2016 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 5 Basel Street Petach Tikva 49131 / IL Opponent's representative Elkington and Fife LLP, et al, et al Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		05 21.01.2016 03.02.2016 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 21.01.2016 29.01.2016 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Building 4 Trident Place Mosquito Way Hatfield Hertfordshire AL10 9UL / GB Opponent's representative Elend, Almut Susanne, et al, et al Venner Shipley LLP Byron House Cambridge Business Park Cowley Road Cambridge, Cambridgeshire CB4 0WZ / GB
		07 21.01.2016 25.01.2016 ADMISSIBLE Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Sanayi Mah. Tunc Cad.No:3 Esenyurt 34555 Istanbul / TR
		08 21.01.2016 02.02.2016 ADMISSIBLE Wittkopp, Alexander Bogenallee 5 20144 Hamburg / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE
		09 22.01.2016 03.02.2016 ADMISSIBLE Galenicum Health S.L. Avenida Diagonal 123, 11th floor 08005 Barcelona / ES Opponent's representative Galenicum Health S.L. Avenida de Cornellà 144, 7th floor 08950 Esplugues de Llobregat / ES
		10 26.01.2016 03.02.2016 ADMISSIBLE ABG Intellectual Property Law, S.L. Avenida de Burgos 16D Edificio Euromor 28036 Madrid / ES Opponent's representative ABG Intellectual Property Law, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES
		11 22.01.2016 03.02.2016 ADMISSIBLE Stolmár, Matthias Blumenstrasse 17 80331 München / DE Opponent's representative Stolmár & Partner Patentanwälte PartG mbB Blumenstraße 17 80331 München / DE
		12 22.01.2016 03.02.2016 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Best, Michael Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstrasse 2 80538 München / DE
		13 22.01.2016 03.02.2016 ADMISSIBLE Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE Opponent's representative Adam, Holger Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE
	Former [2019/03]
	Opponent(s)	01 22.07.2015 11.01.2016 ADMISSIBLE Breuer, Markus Henkel, Breuer & Partner Patentanwälte Brienner Str. 1 80333 München / DE Opponent's representative Ferrer Internacional S.A. Joan Buscallà 1-9 08173 Sant Cugat del Vallès / ES
		02 06.01.2016 19.01.2016 ADMISSIBLE Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Elkington & Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		03 21.01.2016 29.01.2016 ADMISSIBLE ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. ul. Pelplinska 19 83-200 Starogard Gdanski / PL Opponent's representative Elkington & Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		04 21.01.2016 29.01.2016 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 5 Basel Street Petach Tikva 49131 / IL Opponent's representative Elkington & Fife LLP, et al, et al Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		05 21.01.2016 03.02.2016 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 21.01.2016 29.01.2016 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Building 4 Trident Place Mosquito Way Hatfield Hertfordshire AL10 9UL / GB Opponent's representative Elend, Almut Susanne, et al, et al Venner Shipley LLP Byron House Cambridge Business Park Cowley Road Cambridge, Cambridgeshire CB4 0WZ / GB
		07 21.01.2016 25.01.2016 ADMISSIBLE Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Sanayi Mah. Tunc Cad.No:3 Esenyurt 34555 Istanbul / TR
		08 21.01.2016 02.02.2016 ADMISSIBLE Wittkopp, Alexander Bogenallee 5 20144 Hamburg / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE
		09 22.01.2016 03.02.2016 ADMISSIBLE Galenicum Health S.L. Avenida Diagonal 123, 11th floor 08005 Barcelona / ES Opponent's representative Galenicum Health S.L. Avenida de Cornellà 144, 7th floor 08950 Esplugues de Llobregat / ES
		10 26.01.2016 03.02.2016 ADMISSIBLE ABG Patentes, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES Opponent's representative ABG Intellectual Property, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES
		11 22.01.2016 03.02.2016 ADMISSIBLE Stolmár, Matthias Blumenstrasse 17 80331 München / DE Opponent's representative Stolmár & Partner Patentanwälte PartG mbB Blumenstraße 17 80331 München / DE
		12 22.01.2016 03.02.2016 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Best, Michael Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstrasse 2 80538 München / DE
		13 22.01.2016 03.02.2016 ADMISSIBLE Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE Opponent's representative Adam, Holger Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE
	Former [2018/48]
	Opponent(s)	01 22.07.2015 11.01.2016 ADMISSIBLE Breuer, Markus Henkel, Breuer & Partner Patentanwälte Brienner Str. 1 80333 München / DE Opponent's representative Ferrer Internacional S.A. Joan Buscallà 1-9 08173 Sant Cugat del Vallès / ES
		02 06.01.2016 19.01.2016 ADMISSIBLE Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Gillard, Richard Edward Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus London EC1N 2HA / GB
		03 21.01.2016 29.01.2016 ADMISSIBLE ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. ul. Pelplinska 19 83-200 Starogard Gdanski / PL Opponent's representative Gillard, Richard Edward Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus London EC1N 2HA / GB
		04 21.01.2016 29.01.2016 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 5 Basel Street Petach Tikva 49131 / IL Opponent's representative Gillard, Richard Edward, et al, et al Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus London EC1N 2HA / GB
		05 21.01.2016 03.02.2016 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 21.01.2016 29.01.2016 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Building 4 Trident Place Mosquito Way Hatfield Hertfordshire AL10 9UL / GB Opponent's representative Elend, Almut Susanne, et al, et al Venner Shipley LLP Byron House Cambridge Business Park Cowley Road Cambridge, Cambridgeshire CB4 0WZ / GB
		07 21.01.2016 25.01.2016 ADMISSIBLE Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Sanayi Mah. Tunc Cad.No:3 Esenyurt 34555 Istanbul / TR
		08 21.01.2016 02.02.2016 ADMISSIBLE Wittkopp, Alexander Bogenallee 5 20144 Hamburg / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE
		09 22.01.2016 03.02.2016 ADMISSIBLE Galenicum Health S.L. Avenida Diagonal 123, 11th floor 08005 Barcelona / ES Opponent's representative Galenicum Health S.L. Avenida de Cornellà 144, 7th floor 08950 Esplugues de Llobregat / ES
		10 26.01.2016 03.02.2016 ADMISSIBLE ABG Patentes, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES Opponent's representative ABG Intellectual Property, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES
		11 22.01.2016 03.02.2016 ADMISSIBLE Stolmár, Matthias Blumenstrasse 17 80331 München / DE Opponent's representative Stolmár & Partner Patentanwälte PartG mbB Blumenstraße 17 80331 München / DE
		12 22.01.2016 03.02.2016 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Best, Michael Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstrasse 2 80538 München / DE
		13 22.01.2016 03.02.2016 ADMISSIBLE Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE Opponent's representative Adam, Holger Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE
	Former [2018/32]
	Opponent(s)	01 22.07.2015 11.01.2016 ADMISSIBLE Breuer, Markus Henkel, Breuer & Partner Patentanwälte Brienner Str. 1 80333 München / DE Opponent's representative Henkel, Breuer & Partner Patentanwälte Brienner Strasse 1 80333 München / DE
		02 06.01.2016 19.01.2016 ADMISSIBLE Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Gillard, Richard Edward Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus London EC1N 2HA / GB
		03 21.01.2016 29.01.2016 ADMISSIBLE ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. ul. Pelplinska 19 83-200 Starogard Gdanski / PL Opponent's representative Gillard, Richard Edward Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus London EC1N 2HA / GB
		04 21.01.2016 29.01.2016 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 5 Basel Street Petach Tikva 49131 / IL Opponent's representative Gillard, Richard Edward, et al, et al Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus London EC1N 2HA / GB
		05 21.01.2016 03.02.2016 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 21.01.2016 29.01.2016 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Building 4 Trident Place Mosquito Way Hatfield Hertfordshire AL10 9UL / GB Opponent's representative Elend, Almut Susanne, et al, et al Venner Shipley LLP Byron House Cambridge Business Park Cowley Road Cambridge, Cambridgeshire CB4 0WZ / GB
		07 21.01.2016 25.01.2016 ADMISSIBLE Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Sanayi Mah. Tunc Cad.No:3 Esenyurt 34555 Istanbul / TR
		08 21.01.2016 02.02.2016 ADMISSIBLE Wittkopp, Alexander Bogenallee 5 20144 Hamburg / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE
		09 22.01.2016 03.02.2016 ADMISSIBLE Galenicum Health S.L. Avenida Diagonal 123, 11th floor 08005 Barcelona / ES Opponent's representative Galenicum Health S.L. Avenida de Cornellà 144, 7th floor 08950 Esplugues de Llobregat / ES
		10 26.01.2016 03.02.2016 ADMISSIBLE ABG Patentes, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES Opponent's representative ABG Patentes, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES
		11 22.01.2016 03.02.2016 ADMISSIBLE Stolmár, Matthias Blumenstrasse 17 80331 München / DE Opponent's representative Stolmár & Partner Patentanwälte PartG mbB Blumenstraße 17 80331 München / DE
		12 22.01.2016 03.02.2016 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Best, Michael Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstrasse 2 80538 München / DE
		13 22.01.2016 03.02.2016 ADMISSIBLE Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE Opponent's representative Adam, Holger Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE
	Former [2017/47]
	Opponent(s)	01 22.07.2015 11.01.2016 ADMISSIBLE Breuer, Markus Henkel, Breuer & Partner Patentanwälte Brienner Str. 1 80333 München / DE
		02 06.01.2016 19.01.2016 ADMISSIBLE Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Gillard, Richard Edward Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus London EC1N 2HA / GB
		03 21.01.2016 29.01.2016 ADMISSIBLE ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. ul. Peplinska 19 83-200 Starogard Gdanski / PL Opponent's representative Gillard, Richard Edward Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus London EC1N 2HA / GB
		04 21.01.2016 29.01.2016 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 5 Basel Street Petach Tikva 49131 / IL Opponent's representative Gillard, Richard Edward, et al, et al Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus London EC1N 2HA / GB
		05 21.01.2016 03.02.2016 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 21.01.2016 29.01.2016 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Building 4 Trident Place Mosquito Way Hatfield Hertfordshire AL10 9UL / GB Opponent's representative Elend, Almut Susanne, et al, et al Venner Shipley LLP Byron House Cambridge Business Park Cowley Road Cambridge, Cambridgeshire CB4 0WZ / GB
		07 21.01.2016 25.01.2016 ADMISSIBLE Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Sanayi Mah. Tunc Cad.No:3 Esenyurt 34555 Istanbul / TR
		08 21.01.2016 02.02.2016 ADMISSIBLE Wittkopp, Alexander Bogenallee 5 20144 Hamburg / DE Opponent's representative Hamm & Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE
		09 22.01.2016 03.02.2016 ADMISSIBLE Galenicum Health S.L. Avenida Diagonal 123, 11th floor 08005 Barcelona / ES Opponent's representative Galenicum Health S.L. Avenida de Cornellà 144, 7th floor 08950 Esplugues de Llobregat / ES
		10 26.01.2016 03.02.2016 ADMISSIBLE ABG Patentes, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES Opponent's representative ABG Patentes, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES
		11 22.01.2016 03.02.2016 ADMISSIBLE Stolmár, Matthias Blumenstrasse 17 80331 München / DE Opponent's representative Stolmár & Partner Patentanwälte PartG mbB Blumenstraße 17 80331 München / DE
		12 22.01.2016 03.02.2016 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Best, Michael Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstrasse 2 80538 München / DE
		13 22.01.2016 03.02.2016 ADMISSIBLE Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE Opponent's representative Adam, Holger Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE
	Former [2016/51]
	Opponent(s)	01 22.07.2015 11.01.2016 ADMISSIBLE Breuer, Markus Henkel, Breuer & Partner Patentanwälte Erika-Mann-Strasse 23 80636 München / DE
		02 06.01.2016 19.01.2016 ADMISSIBLE Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Gillard, Richard Edward Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus London EC1N 2HA / GB
		03 21.01.2016 29.01.2016 ADMISSIBLE ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. ul. Peplinska 19 83-200 Starogard Gdanski / PL Opponent's representative Gillard, Richard Edward Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus London EC1N 2HA / GB
		04 21.01.2016 29.01.2016 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 5 Basel Street Petach Tikva 49131 / IL Opponent's representative Gillard, Richard Edward, et al, et al Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus London EC1N 2HA / GB
		05 21.01.2016 03.02.2016 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 21.01.2016 29.01.2016 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Building 4 Trident Place Mosquito Way Hatfield Hertfordshire AL10 9UL / GB Opponent's representative Elend, Almut Susanne, et al, et al Venner Shipley LLP Byron House Cambridge Business Park Cowley Road Cambridge, Cambridgeshire CB4 0WZ / GB
		07 21.01.2016 25.01.2016 ADMISSIBLE Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Sanayi Mah. Tunc Cad.No:3 Esenyurt 34555 Istanbul / TR
		08 21.01.2016 02.02.2016 ADMISSIBLE Wittkopp, Alexander Bogenallee 5 20144 Hamburg / DE Opponent's representative Hamm & Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE
		09 22.01.2016 03.02.2016 ADMISSIBLE Galenicum Health S.L. Avenida Diagonal 123, 11th floor 08005 Barcelona / ES Opponent's representative Galenicum Health S.L. Avenida de Cornellà 144, 7th floor 08950 Esplugues de Llobregat / ES
		10 26.01.2016 03.02.2016 ADMISSIBLE ABG Patentes, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES Opponent's representative ABG Patentes, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES
		11 22.01.2016 03.02.2016 ADMISSIBLE Stolmár, Matthias Blumenstrasse 17 80331 München / DE Opponent's representative Stolmár & Partner Patentanwälte PartG mbB Blumenstraße 17 80331 München / DE
		12 22.01.2016 03.02.2016 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Best, Michael Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstrasse 2 80538 München / DE
		13 22.01.2016 03.02.2016 ADMISSIBLE Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE Opponent's representative Adam, Holger Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE
	Former [2016/10]
	Opponent(s)	01 22.07.2015 11.01.2016 ADMISSIBLE Breuer, Markus Henkel, Breuer & Partner Patentanwälte Erika-Mann-Strasse 23 80636 München / DE
		02 06.01.2016 19.01.2016 ADMISSIBLE Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Gillard, Richard Edward Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus London EC1N 2HA / GB
		03 21.01.2016 29.01.2016 ADMISSIBLE ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. ul. Peplinska 19 83-200 Starogard Gdanski / PL Opponent's representative Gillard, Richard Edward Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus London EC1N 2HA / GB
		04 21.01.2016 29.01.2016 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 5 Basel Street Petach Tikva 49131 / IL Opponent's representative Ter Meer Steinmeister & Partner, et al, et al Patentanwälte mbB Nymphenburger Straße 4 80335 München / DE
		05 21.01.2016 03.02.2016 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 21.01.2016 29.01.2016 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Building 4 Trident Place Mosquito Way Hatfield Hertfordshire AL10 9UL / GB Opponent's representative Elend, Almut Susanne, et al, et al Venner Shipley LLP Byron House Cambridge Business Park Cowley Road Cambridge, Cambridgeshire CB4 0WZ / GB
		07 21.01.2016 25.01.2016 ADMISSIBLE Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Sanayi Mah. Tunc Cad.No:3 Esenyurt 34555 Istanbul / TR
		08 21.01.2016 02.02.2016 ADMISSIBLE Wittkopp, Alexander Bogenallee 5 20144 Hamburg / DE Opponent's representative Hamm & Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE
		09 22.01.2016 03.02.2016 ADMISSIBLE Galenicum Health S.L. Avenida Diagonal 123, 11th floor 08005 Barcelona / ES Opponent's representative Galenicum Health S.L. Avenida de Cornellà 144, 7th floor 08950 Esplugues de Llobregat / ES
		10 26.01.2016 03.02.2016 ADMISSIBLE ABG Patentes, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES Opponent's representative ABG Patentes, S.L. Avenida de Burgos, 16D Edificio Euromor 28036 Madrid / ES
		11 22.01.2016 03.02.2016 ADMISSIBLE Stolmár, Matthias Blumenstrasse 17 80331 München / DE Opponent's representative Stolmár & Partner Patentanwälte PartG mbB Blumenstraße 17 80331 München / DE
		12 22.01.2016 03.02.2016 ADMISSIBLE Hexal AG Industriestrasse 25 83607 Holzkirchen / DE Opponent's representative Best, Michael Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstrasse 2 80538 München / DE
		13 22.01.2016 03.02.2016 ADMISSIBLE Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE Opponent's representative Adam, Holger Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE
	Former [2016/09]
	Opponent(s)	01 22.07.2015 11.01.2016 ADMISSIBLE Breuer, Markus Henkel, Breuer & Partner Patentanwälte Erika-Mann-Strasse 23 80636 München / DE
		02 06.01.2016 19.01.2016 ADMISSIBLE Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Gillard, Richard Edward Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus London EC1N 2HA / GB
		03 21.01.2016 ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. ul. Peplinska 19 83-200 Starogard Gdanski / PL Opponent's representative Gillard, Richard Edward Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus London EC1N 2HA / GB
		04 21.01.2016 Teva Pharmaceutical Industries Ltd. 5 Basel Street Petach Tikva 49131 / IL Opponent's representative Ter Meer Steinmeister & Partner, et al, et al Patentanwälte mbB Nymphenburger Straße 4 80335 München / DE
		05 21.01.2016 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		06 21.01.2016 ADMISSIBLE Generics [UK] Limited (trading as Mylan) Building 4 Trident Place Mosquito Way Hatfield Hertfordshire AL10 9UL / GB Opponent's representative Elend, Almut Susanne, et al, et al Venner Shipley LLP Byron House Cambridge Business Park Cowley Road Cambridge, Cambridgeshire CB4 0WZ / GB
		07 21.01.2016 ADMISSIBLE Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Sanayi Mah. Tunc Cad.No:3 Esenyurt 34555 Istanbul / TR
		08 21.01.2016 Wittkopp, Alexander Bogenallee 5 20144 Hamburg / DE
		09 22.01.2016 Galenicum Health S.L. Avenida Diagonal 123 floor 11 08005 Barcelona / ES
	Former [2016/07]
	Opponent(s)	01 22.07.2015 11.01.2016 ADMISSIBLE Breuer, Markus Henkel, Breuer & Partner Patentanwälte Erika-Mann-Strasse 23 80636 München / DE
		02 06.01.2016 Actavis Group PTC ehf Reykjavikurvegi 76-78 220 Hafnarfjördur / IS Opponent's representative Gillard, Richard Edward Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus London EC1N 2HA / GB
	Former [2015/36]
	Opponent(s)	01 22.07.2015 Breuer, Markus Henkel, Breuer & Partner Patentanwälte Erika-Mann-Strasse 23 80636 München / DE
	13.08.2015	No. 01: Notification indicating deficiencies in the notice of opposition
	30.12.2015	No. 01: Reply to notification indicating deficiencies in the notice of opposition
	07.03.2016	Invitation to proprietor to file observations on the notice of opposition
	16.11.2016	Reply of patent proprietor to notice(s) of opposition
	05.02.2018	Date of oral proceedings
	30.04.2018	Despatch of minutes of oral proceedings
	27.10.2021	Legal effect of rejection of opposition [2022/31]
	29.06.2022	Date of despatch of rejection of opposition
Appeal following opposition	03.07.2018	Appeal received No. T1732/18
	10.09.2018	Statement of grounds filed
	27.10.2021	Result of appeal procedure: maintenance in unamended form
	16.05.2022	Despatch of the decision of the Board of Appeal
	26.10.2021	Date of oral proceedings
Petition(s) for review:	21.07.2022	Petition for review received
		Number: R0017/22
		for appeal No. T1732/18-3301
		Petitioner: OP03
	15.12.2023	Decision: Withdrawal of the petition for review.
Fees paid	Renewal fee
	31.01.2008	Renewal fee patent year 03
	22.03.2008	Renewal fee patent year 04
	01.02.2010	Renewal fee patent year 05
	31.01.2011	Renewal fee patent year 06
	11.01.2012	Renewal fee patent year 07
	10.01.2013	Renewal fee patent year 08
	21.01.2014	Renewal fee patent year 09
	13.01.2015	Renewal fee patent year 10
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[XD]US2003153610 (STRAUB ALEXANDER [DE], et al) [XD] 1-8 * paragraphs [0003] , [0008] - [0011] - [0356] , [0366] , [0367] , [0373]; example 44; claims 10-15 *;
		[XD] - KUBITZA DAGMAR ET AL, "Multiple dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct Factor Xa inhibitor in healthy male subjects.", BLOOD, & 45TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 06-09, 2003, (20031116), vol. 102, no. 11, ISSN 0006-4971, page 811a, XP009050847 [XD] 1-8 * abstract *
		[X] - KUBITZA DAGMAR ET AL, "Single dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct factor Xa inhibitor in healthy male subjects.", BLOOD, & 45TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 06-09, 2003, (20031116), vol. 102, no. 11, ISSN 0006-4971, page 813a, XP009050848 [X] 1-8 * abstract *
	by applicant	WO0147919
		- GOODMAN; GILLMANS, The Pharmacological Basis of Therapeutics, MACMILLAN PUBLISHING COMPANY, (1985), page 27
		- MALCOLM ROWLAND; THOMAS N. TOZER, Clinical Pharmacokinetics, Concepts and Applications, LEA AND FEBIGER, (1995), page 83
		- DONALD J. BIRKETT, Pharmacokinetics Made Easy, MCGRAW-HILL EDUCATION, (2000), page 20
		- GOODMAN; GILLMANS, The Pharmacological Basis of Therapeutics, MACMILLAN PUBLISHING COMPANY, (1985), page 28
		- D. KUBITZA ET AL., "Multiple dose escalation study investigating the pharmacodynamics", SAFETY, AND PHARMACOKINETICS OF BAY, pages 59 - 7939
		- "an oral, direct Factor Xa inhibitor, in healthy male subjects", BLOOD, (2003), vol. 102
		- "the Sixth ACCP Consensus Conference on Antithrombotic Therapy", CHEST, (2001), vol. 119, pages 132S - 175S
	other	- Anonymous, "Xarelto rivaroxaban tablets & oral suspension", Janssen Pharmaceuticals, (20220101), pages 1 - 8, XP093050132
		- D J Birkett, "PHARMACOKINETICS MADE EASY 11 DESIGNING DOSE REGIMENS. ", Aust Prescr., (19960701), (20140827), XP055136785
		US2003153610
		- KUBITZA D ET AL., "MULTIPLE DOSE ESCALATION STUDY INVESTIGATING THE PHARMACODYNAMICS, SAFETY, AND PHARMACOKINETICS OF BAY 59-7939 AN ORAL, DIRECT FACTOR XA INHIBITOR IN HEALTHY MALE SUBJECTS", BLOOD, (20031116), vol. 102, no. 11, page 811A, XP009050847
		- KUBITZA D. ET AL, "INGLE DOSE ESCALATION STUDY INVESTIGATING THE PHARMACODYNAMICS, SAFETY, AND PHARMACOKINETICS OF BAY 59-7939 AN ORAL, DIRECT FACTOR XA INHIBITOR IN HEALTHY MALE SUBJECTS", BLOOD, (20031116), vol. 102, no. 11, page 813A, XP009050848
	Opposition	US2003153610
		WO0147919
		US2007026065
		- E. PERZBORN et al., "In vitro and in-vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor", Journal of Thrombosis and Haemostasis, (20050126), vol. 3, pages 514 - 521, XP055297385
		- D. KUBITZA et al., "Multiple Dose Escalation Study Investigating the Pharmacody- namics, Safety, and Pharmacokinetics of BAY 59-7939 an Oral, Direct Factor Xa Inhibitor in Healthy Male Subjects", Abstract# 3004 in: blood, (20030000), vol. 102, no. 11, page 811 a, XP019421008 DOI: http://dx.doi.org/10.1007/s00228-005-0043-5
		- S. HARDER et al., "Effects of BAY 59-7939, an Oral Direct Factor Xa Inhibitor, on Thrombin Generation in Healthy Volunteers", Abstract# 3003 in: blood, (20030000), vol. 102, no. 11, page 811a
		- D. KUBITZA et al., "Single Dose Escalation Study investigating the Pharmacody- namics, Safety, and Pharmacokinetics of BAY 59-7939 an Oral, Direct Factor Xa Inhibitor in Healthy Male Subjects", Abstract# 3010 in: blood, (20030000), vol. 102, no. 11, page 813a, XP019421008 DOI: http://dx.doi.org/10.1007/s00228-005-0043-5
		- RITSCHEL, BAUER-BRANDL, Die Tablette, (20020000), page 1
		- C. KEARON et al., "Duration of Venous Thromboembolism Prophylaxis After Surgery", Chest, (20031200), vol. 124, no. 6 Suppl., pages 386S - 392S, XP055298108 DOI: http://dx.doi.org/10.1378/chest.124.6_suppl.386S
		- D. KUBITZA et al., "Multiple dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct Factor Xa inhibitor in healthy male subjects.", Blood, San Diego , CA , USA ;, (20031200), vol. 102, no. 11, 16, page 811a, XP009050847
		- D. KUBITZA et al., "Single dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct Factor Xa inhibitor in healthy male subjects.", Blood, San Diego , CA , USA ;, (20031200), vol. 102, no. 11, 16, page 813a, XP009050848
		- Pharmaceutics: The Science of Dosage Form Design, (20020000), pages 410 - 411, XP055274663
		- H.A. LIEBERMAN et al., "compressed tablets by wet granulation", Pharmaceutical Dosage Forms: Tablets, (19890000), vol. 1, page 131, XP002558516
		- R. J. LEADLEY, "Coagulation Factor Xa Inhibition: Biological Background and Rationale", Current Topics in Medicinal Chemistry, (20010000), vol. 1, pages 151 - 159, XP055292158
		- R.W. FOSTER, Basic Pharmacology, (19800000), page 255, XP055292156
		- HARDER et al., "Effects of BAY 59-7939, an innovative, oral, direct Factor Xa inhibitor, on thrombin generation in healthy volunteers", Pathophysiol Haemost Thromb, (20030000), vol. 33, no. suppl2, page O 078, XP055298764
		- "Enoxaparin Clinical Pearl", Cleveland Clinic Pharmacotherapy Update, (20030100), vol. VI, no. 1
		- FAREED et al., "Studies on the mechanism of action of BAY 59-7939 - an oral, direct Factor Xa inhibitor", Pathophysiol Haemost Thromb, (20030000), vol. 33, no. suppl2, page O 077, XP055298766
		- PERZBORN et al., "In vitro and in vivo studies of the novel antithrombotic agent BAY 59- 7939 - an oral, direct Factor Xa inhibitor", Journal of Thrombosis and Haemostasis, vol. 3, pages 514 - 521, XP009050814 DOI: http://dx.doi.org/10.1111/j.1538-7836.2005.01166.x
		- KUBITZA et al., "Multiple dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct factor Xa inhibitor in healthy male subjects", BLOOD, (20031116), vol. 102, no. 11, page 811 a, XP009050847
		- KUBITZA, D. et al., "Multiple Dose Escalation Study Investigating the Pharmacodynamics, Safety, and Pharmacokinetics of BAY 59-7939 an Oral, Direct Factor Xa Inhibitor in Healthy Male Subjects", Blood, (20030000), vol. 102, no. 11, page 811a
		- KUBITZA, D. et al., "Single Dose Escalation Study Investigating the Pharmacodynamics, Safety, and Pharmacokinetics of BAY 59-7939 an Oral, Direct Factor Xa Inhibitor in Healthy Male Subjects", Blood, (20030000), vol. 102, no. 11, page 813a
		- KUBITZA, D. et al., "Multiple dose escalation study investigating BAY 59-7939 - an oral, direct factor Xa inhibitor - in healthy male subjects", Pathophysiology of Haemostasis and Thrombosis, (20030000), vol. 33, no. suppl2, page 98
		- HARDER, S. et al., "Effects of BAY 59-7939, an innovative, oral, direct factor Xa inhibitor, on thrombin generation in healthy volunteers", Pathophysiology of Haemostasis and Thrombosis, (20030000), vol. 33, no. suppl2, page 97
		- ROWLAND, M. et al., Clinical Pharmacokinetics - Concepts and Applications, (19950000), ISBN 0-683-07404-0, pages 83 - 92
		- DERENDORF, H. et al., ?Pharmakokinetik - Einfuhrung in die Theorie und Relevanz fur die Arzneimitteltherapie, (20020000), ISBN 3-8047-1907-4, pages 16 - 57
		- WEINZ, C. et al., "Metabolism and Distribution of [14C]BAY 59-7939 - an Oral, Direct Factor Xa Inhibitor - in Rat, Dog and Human", Drug Metabolism Reviews, (20040000), vol. 36, no. suppll, page 98, XP009063377
		- VRIJENS, B. et al., "?Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence", Europa ce, (20150000), vol. 17, pages 514 - 523, XP055298770 DOI: http://dx.doi.org/10.1093/europace/euu311
		- OBERPICHLER-SCHWENK, H., "Rivaroxaban", Medizinische Monatsschrift für Pharmazeuten, (20080000), vol. 31, no. 11, pages 412 - 416
		- KUBITZA et al., "Mutliple dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct factor Xa inhibitor in healthy male subjects", Blood, (20030000), vol. 102, no. 11, XP055298763
		- KUBITZA et al., "Single dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct factor Xa inhibitor in healthy male subjects", Blood, (20030000), vol. 102, no. 11, XP009050848
		- HARDER et al., "Effects of BAY 59-7939, an innovative, oral, direct factor Xa inhibitor, on thrombin generation in healthy volunteers", Pathophysiol. Haemost. Thromb ., (20030000), vol. 33, no. Suppl. 2, page 97, XP055298761
		- KUBITZA, D. et al., "Multiple dose escalation study investigating the pharmacodynamics, safety and pharmacokinetics of BAY 59-7939 an oral, direct factor Xa inhibitor in healthy male subjects'';", Blood, (20031116), vol. 102, no. 11, page 811a, XP009050847
		- KUBITZA, D. et al., "Single dose escalation study investigating the pharmacodynamics, safety and pharmacokinetics of BAY 59-7939 an oral, direct factor Xa inhibitor in healthy male subjects'';", Blood, (20031116), vol. 102, no. 11, page 813a, XP019421008 DOI: http://dx.doi.org/10.1007/s00228-005-0043-5
		- LIEBERMAN, A. et al., "Pharmaceutical dosage forms'';", (19800000), vol. 1 -Table, pages 172 - 181 ;
		- SOFIA MATTSSON, "Pharmaceutical Binders and Their Function in Directly Compressed Tablets - Mechanistic Studies on the Effect of Dry Binders on Mechanical Strength, Pore Structure and Disintegration of Tablets'';", Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy, (20000000), vol. 238
		- RASENACK N. et al., "Crystal habit and tableting behaviour'';", International Journal of Pharmaceutics, (20020000), vol. 244, pages 45 - 57, XP055291502 DOI: http://dx.doi.org/10.1016/S0378-5173(02)00296-X
		- DAGMAR KUBITZA et al., "Multiple dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct, Factor Xa inhibitor in healthy male subjects", BLOOD, (20031116), vol. 102, no. 11, page 811a, XP019421008 DOI: http://dx.doi.org/10.1007/s00228-005-0043-5
		- DAGMAR KUBITZA et al., "Single dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral direct Factor Xa inhibitor in healthy male subjects", BLOOD, (20031116), vol. 102, no. 11, page 813a
		- S. HARDER et al., "Effects of BAY 59-7939, an innovative, oral, direct factor Xa inhibitor, on thrombin generation in healthy volunteers", Pathophysiol Haemost Thromb, (20030000), vol. 33, no. supplement 2
		- J. FAREED et al., "Pharmacodynamic and Pharmacokinetic Properties of Enoxaparin: Implications for Clinical Practice", Clin Pharmacokinet, (20030000), vol. 42, no. 12, pages 1043 - 1057, XP008035665 DOI: http://dx.doi.org/10.2165/00003088-200342120-00003
		- R. LEADLEY et al., "Coagulation Factor Xa Inhibition: Biological Background and Rationale", Current Topics in Medicinal Chemistry, (20010000), vol. 1, pages 151 - 159, XP055292158
		- FAREED J; ET AL, "PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES OF ENOXAPARIN IMPLICATIONS FOR CLINICAL PRACTICE", Clin Pharmacokinet, (20030000), vol. 42, pages 1043 - 1057, XP008035665 DOI: http://dx.doi.org/10.2165/00003088-200342120-00003
		- "Approval PACKAGE FOR Application Number NDA 20-164/S-055", FDA, (20040723), pages 1 - 90, XP055442448
		- "not more than", Merriam-Webster Online Dictionary, (20111130), URL: https://www.merriam- webster .com/ di ctiona rv /no/not%20more%20tha n, XP055442450
		- "Questions and Answers for Cialis (tadalafil", FDA, (20111130), pages 1 - 3, URL: https://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm118692.htm, XP055442451
		- LAUX, V et al., "Preclinical and Clinical Characteristics of Rivaroxaban: a novel, oral, direct Factor Xa inhibitor", Sem Thromb Hemostasis, (20070000), vol. 33, no. 5, pages 515 - 523, XP055442455 DOI: http://dx.doi.org/10.1055/s-2007-982083
		- KUBITZA, D et al., "Safety, pharmacodynamics and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects", Eur J Clin Pharma, (20050000), vol. 61, pages 873 - 880, XP019421008 DOI: http://dx.doi.org/10.1007/s00228-005-0043-5
		- PERZBORN, E et al., "The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor", Nat Rev Drug Discovery, (20110000), vol. 10, pages 61 - 75, XP055111223 DOI: http://dx.doi.org/10.1038/nrd3185
		- GRAFF, J et al., "Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet-Induced Thrombin Generation and Prothrombinase Activity", J Clin Pharmacol, (20070000), vol. 47, pages 1398 - 1407, XP008101055 DOI: http://dx.doi.org/10.1177/0091270007302952
		- KUBITZA, D et al., "The discovery of Rivaroxaban: translating preclinical assessments into clinical practice", Fron Pharm, (20130000), vol. 4, XP055442466
		- KUBITZA, D et al., "Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications", Clin Appl Thromb/Hemostasis, (20160000), vol. 22, no. 5, pages 412 - 422
		- KUBITZA et al., "MULTIPLE DOSE ESCALATION STUDY INVESTIGATING THE PHARMACODYNAMICS, SAFETY, AND PHARMACOKINETICS OF BAY 59-7939 AN ORAL, DIRECT FACTOR XA INHIBITOR IN HEALTHY MALE SUBJECTS", Blood, 811A, (20030000), vol. 102, no. 11, XP009050847
		- JOEL G. HARDMAN et al., "CHAPETR 1", The Pharmacological Basis of Therapeutics, Goodman and Gilman's, (20010000), pages 1 - 29, XP055578938
		- "Rote Liste", (20040000), pages 1 - 3
		- KUBITZA et al., "SINGLE DOSE ESCALATION STUDY INVESTIGATING THE PHARMACODYNAMICS, SAFETY, AND PHARMACOKINETICS OF BAY 59-7939 AN ORAL, DIRECT FACTOR XA INHIBITOR IN HEALTHY MALE SUBJECTS", Pathophysiol. Haemost. Thromb., (20030000), vol. 33, no. 2, page 98, XP009050848
		- FAREED et al., "PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES OF ENOXAPARIN IMPLICATIONS FOR CLINICAL PRACTICE", Clin Pharmacokinet, (20030000), vol. 42, no. 12, pages 1043 - 1057, XP008035665 DOI: http://dx.doi.org/10.2165/00003088-200342120-00003
		- MALCOLM ROWLAND et al., "Excerts from Chapter 1 and 7", Clinical Pharmacokinetics Concepts and Applications third edition, Philadelphia, (19950000), pages 83 - 105, XP055484785
		- HARDER et al., "Effects of BAY 59-7939, an innovative, oral, direct factor Xa inhibitor, on thrombin generation in healthy volunteers", Pathophysiol. Haemost. Thromb., (20030000), vol. 33, no. 2, page 97, XP055298761
		- PERZBORN et al., "IN VITRO AND IN VIVO STUDIES OF THE NOVEL ANTITHROMBOTIC AGENT BAY 59-7939-AN ORAL, DIRECT FACTOR XA INHIBITOR", J. Thromb. Haemost., vol. 3, no. 3, (20050300), pages 514 - 21, (20050126), XP009050814 DOI: http://dx.doi.org/10.1111/j.1538-7836.2005.01166.x
		- KUBITZA DAGMAR et al., "Multiple dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59- 7939 an oral, direct Factor Xa inhibitor in healthy male subjects.", BLOOD, (20031116), vol. 102, no. 11, page 811a, XP009050847
		- KUBITZA DAGMAR et al., "Single dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59- 7939 an oral, direct Factor Xa inhibitor in healthy male subjects.", BLOOD, (20031116), vol. 102, no. 11, page 813a, XP009050848
		- KUBITZA DAGMAR et al., "Multiple dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct Factor Xa inhibitor in healthy male subjects''.", Blood, (20031116), vol. 102, no. 11, page 811a, XP009050847
		- KUBITZA DAGMAR et al., "Single dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct Factor Xa inhibitor in healthy male subjects''.", Blood, San Diego , CA , USA, (20031116), vol. 102, no. 11, page 813a, XP009050848
	- KUBITZA DAGMAR et al., "Effects of BAY 59-7939, an Oral Direct Factor Xa Inhibitor, on Thrombin Generation in Healthy Volunteers''.", Blood, (20031116), vol. 102, no. 11, page 811a
	- MALCOLM ROWLAND et al., "Clinical Pharmacokinetics, concepts and applications", Lea and Febiger, Philadelphia, (19950000), pages 1 - 7, XP055298784
	- E. PERZBORN et al., "In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor", Journal of Thrombosis and Haemostasis, vol. 3, no. 3, (20050000), pages 514 - 521, (20050126), XP009050814 DOI: http://dx.doi.org/10.1111/j.1538-7836.2005.01166.x
	- KUBITZA, DAGMAR et al., "Multiple dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral direct Factor Xa inhibitor in healthy male subjects", Blood, San Diego , CA USA, (20031116), vol. 102, no. 11, page 811a, XP009050847
	- KUBITZA, DAGMAR et al., "Single dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral direct Factor Xa inhibitor in healthy male subjects", Blood, San Diego , CA USA, (20031116), vol. 102, no. 11, page 813a, XP009050848
	- PERZBORN, E et al., "In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor", Journal of Thrombosis and Haemostasis, (20050124), vol. 3, pages 514 - 521, XP009050814 DOI: http://dx.doi.org/10.1111/j.1538-7836.2005.01166.x
	- BIRKETT, D.J., "Pharmacokinetics made easy 11 Designing Dose Regimens", Aust Prescr, (19960701), vol. 19, pages 76 - 78, XP055136785
	- HARDER, SEBASTIAN et al., "Effects of BAY 59-7939, an oral direct Factor Xa inhibitor, on Thrombin Generation in Healthy Volunteers", Blood, San Diego , CA USA, (20031116), vol. 102, no. 11, page 811a, XP009050847
	- KUBITZA D et al., "Multiple dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct factor Xa inhibitor in healthy male subjects", Blood, (20031116), vol. 102, no. 11, page 811A, XP009050847
	- KUBITZA D et al., "PO080 Multiple dose escalation study investigating BAY 59-7939 - an oral, direct factor Xa inhibitor - in healthy male subjects", Pathophysiol Haemost Thromb, (20030000), vol. 33, no. suppl 2, page 98, XP055792755
	- HARDER S et al., "Effects of BAY 59-7939, an oral, direct factor Xa inhibitor, on thrombin generation in healthy volunteers", Blood, (20030000), vol. 102, no. 11
	- KUBITZA D, ET AL., "MULTIPLE DOSE ESCALATION STUDY INVESTIGATING THE PHARMACODYNAMICS, SAFETY, AND PHARMACOKINETICS OF BAY 59-7939 AN ORAL, DIRECT FACTOR XA INHIBITOR IN HEALTHY MALE SUBJECTS", Blood, American Society of Hematology, US, US , (20031116), vol. 102, no. 11, ISSN 0006-4971, page 811A, XP009050847
	- Kubitza D., Becka M., Wensing G. , Voith B., Zuehlsdorf M, "PO080 Multiple dose escalation study investigating BAY 59-7939 - an oral, direct factor Xa inhibitor - in healthy male subjects", Pathophysiology of Haemostasis and Thrombosis 18th International Congress on Thrombosis (2004), (20030101), vol. 33, no. suppl 2, page 98, XP055792755
	- Harder Et Al., "Effects of BAY 59-7939, an innovative, oral, direct Factor Xa inhibitor, on thrombin generation in healthy volunteers", Pathophysiol Haemost Thromb, (20030101), XP055298764
	- Harder Sebastian et al.,, "Abstract# 3003 Effects of BAY 59-7939, an oral, direct factor Xa inhibitor, on thrombin generation in healthy volunteers", Blood, (20030101), vol. 102, no. 11, XP055966266
	- Samama Mm, Gerotziafas G, "SY59 Synthetic Factor Xa inhibitors", Pathophysiol Haemost Thromb, (20030101), vol. 33, no. Suppl.2, pages 19 - 20, XP055966271
	- PERZBORN et al., In vitro and in vivo ..., J Thromb Haemost, (20050000), vol. 3, no. 3, pages 514 - 521
	- PATRONO et al., "Platelet Active Drugs", Chest, (20010000), vol. 119, no. 1, pages 39S - 63S, XP055298783 DOI: http://dx.doi.org/10.1378/chest.126.3_suppl.234S
	- MUECK et al., "clinical pharmacokinetic and pharmacodynamics profile of rivaroxaban", Clin. Pharmacokinet, (20140000), vol. 53, pages 1 - 16, XP055298782 DOI: http://dx.doi.org/10.1007/s40262-013-0100-7
	- Dose ranging study of Once Daily Regimen of BAY 59- 7939
	- CHARBONNIER et al., "comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis", Thromb. Haemost, (19980000), vol. 79, no. 5, pages 897 - 901, XP055298780
	- TURPIE et al., "an oral direct factor xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement", J.Thromb. Haemostat., (20050000), vol. 3, pages 2479 - 2486, XP055298779
	- KUBITZA et al., "Safety, Pharmacokinetics etc of BAY 59-7939..", Clin . Pharm. Therapeutics, (20050000), vol. 78, no. 4, pages 412 - 21
	- GRIFFIN et al., The Textbook of Pharmaceutical Medicine, (20020000), XP055298778
	- US Pharmacopeia USP 38 NF-33
	- HARRON, DEAN W.G. et al., "Bopindolol - A Review of its Pharacodynamic and Pharmacokinetic ...", Drugs, (19910000), vol. 41, no. 1, pages 130 - 149

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.32; 35p